AJP - Heart AJP citation statistics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 283: H1481-H1488, 2002. First published June 13, 2002; doi:10.1152/ajpheart.01089.2001
0363-6135/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/4/H1481    most recent
01089.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (50)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schulman, D.
Right arrow Articles by Yellon, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulman, D.
Right arrow Articles by Yellon, D. M.
Vol. 283, Issue 4, H1481-H1488, October 2002

Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway

Daniel Schulman1,2, David S. Latchman2, and Derek M. Yellon1

1 The Hatter Institute for Cardiovascular Studies, University College London Hospital and Medical School, London WC1E 6DB; and 2 The Institute of Child Health, University College London, London WC1N 1EH, United Kingdom

Reperfusion of ischemic myocardium is essential for tissue salvage but paradoxically contributes to cell death. We hypothesized that activation of potential survival pathways such as p42/p44 MAPK may prevent lethal reperfusion injury. Urocortin is a peptide factor that affects the p42/p44 MAPK signaling pathway. Both isolated and in vivo rat heart models were used to examine the potential for urocortin to prevent reperfusion injury. Isolated rat hearts underwent 35-min regional ischemia and 2-h reperfusion, with urocortin perfused for 20 min from the onset of reperfusion. In the in vivo study, urocortin was administered as an intravenous bolus 3 min before reperfusion with a protocol of 25-min regional ischemia and 2-h reperfusion. Blockade of the p42/p44 MAPK pathway with the inhibitor PD-98059 was used in both models. Urocortin attenuated lethal reperfusion-induced injury both in vitro and in vivo via a p42/p44 MAPK-dependent mechanism. Furthermore, Western blot analysis demonstrated the ability of urocortin to directly upregulate this signaling pathway. In conclusion, we believe that the p42/p44 MAPK-dependent signaling pathway represents an important survival mechanism against reperfusion injury.

experimental; organ; molecular biology; ischemia; infarction


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
D. J. Hausenloy and D. M. Yellon
Cardioprotective growth factors
Cardiovasc Res, July 15, 2009; 83(2): 179 - 194.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Mizukami, K. Ono, C.-K. Du, T. Aki, N. Hatano, Y. Okamoto, Y. Ikeda, H. Ito, K. Hamano, and S. Morimoto
Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion
Cardiovasc Res, September 1, 2008; 79(4): 589 - 599.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. A. Townsend, S. M. Davidson, S. J. Clarke, I. Khaliulin, C. J. Carroll, T. M. Scarabelli, R. A. Knight, A. Stephanou, D. S. Latchman, and A. P. Halestrap
Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H928 - H938.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. V. Solenkova, V. Solodushko, M. V. Cohen, and J. M. Downey
Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H441 - H449.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Tsang, D. J. Hausenloy, and D. M. Yellon
Myocardial postconditioning: reperfusion injury revisited
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H2 - H7.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
P. van der Meer, E. Lipsic, R. H. Henning, R. A. de Boer, A. J.H. Suurmeijer, D. J. van Veldhuisen, and W. H. van Gilst
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury
Eur J Heart Fail, December 1, 2004; 6(7): 853 - 859.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. M. Kittleson, S. Q. Ye, R. A. Irizarry, K. M. Minhas, G. Edness, J. V. Conte, G. Parmigiani, L. W. Miller, Y. Chen, J. L. Hall, et al.
Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy
Circulation, November 30, 2004; 110(22): 3444 - 3451.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Seubert, B. Yang, J. A. Bradbury, J. Graves, L. M. Degraff, S. Gabel, R. Gooch, J. Foley, J. Newman, L. Mao, et al.
Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K+ Channels and p42/p44 MAPK Pathway
Circ. Res., September 3, 2004; 95(5): 506 - 514.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. G. Corbucci, C. Perrino, G. Donato, A. Ricchi, B. Lettieri, G. Troncone, C. Indolfi, M. Chiariello, and E. V. Avvedimento
Transient and reversible deoxyribonucleic acid damage in human left ventricle under controlled ischemia and reperfusion
J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1992 - 1999.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. R. Gross, A. K. Hsu, and G. J. Gross
Opioid-Induced Cardioprotection Occurs via Glycogen Synthase Kinase {beta} Inhibition During Reperfusion in Intact Rat Hearts
Circ. Res., April 16, 2004; 94(7): 960 - 966.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. J Hausenloy and D. M Yellon
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway
Cardiovasc Res, February 15, 2004; 61(3): 448 - 460.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online